These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 15907389)

  • 1. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes].
    Siberil S; Dutertre CA; Boix C; Teillaud JL
    Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Historical development of monoclonal antibody therapeutics.
    Nissim A; Chernajovsky Y
    Handb Exp Pharmacol; 2008; (181):3-18. PubMed ID: 18071939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges.
    Teillaud JL
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S15-27. PubMed ID: 16187937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three decades of human monoclonal antibodies: past, present and future developments.
    Steinitz M
    Hum Antibodies; 2009; 18(1-2):1-10. PubMed ID: 19478393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-chain antibodies as diagnostic tools and therapeutic agents.
    Hagemeyer CE; von Zur Muhlen C; von Elverfeldt D; Peter K
    Thromb Haemost; 2009 Jun; 101(6):1012-9. PubMed ID: 19492141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
    Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
    Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
    Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
    Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
    Kipriyanov SM; Le Gall F
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered antibodies take center stage.
    Huston JS; George AJ
    Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal and recombinant antibodies, 30 years after ..
    Laffly E; Sodoyer R
    Hum Antibodies; 2005; 14(1-2):33-55. PubMed ID: 16424599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescent cocaine probes: a tool for the selection and engineering of therapeutic antibodies.
    Meijler MM; Kaufmann GF; Qi L; Mee JM; Coyle AR; Moss JA; Wirsching P; Matsushita M; Janda KD
    J Am Chem Soc; 2005 Mar; 127(8):2477-84. PubMed ID: 15725002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.
    Deyev SM; Lebedenko EN
    Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic antibodies and related products: choosing the right structure for success].
    Beck A; Wagner-Rousset E; Wurch T; Corvaia N
    Med Sci (Paris); 2009 Dec; 25(12):1024-32. PubMed ID: 20035674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection, design, and engineering of therapeutic antibodies.
    Presta LG
    J Allergy Clin Immunol; 2005 Oct; 116(4):731-6; quiz 737. PubMed ID: 16210043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibodies for cancer therapy.
    Chames P; Baty D
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):276-83. PubMed ID: 19333873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
    Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
    J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Monoclonals antibodies: a recent and major therapeutic advance].
    Paintaud G; Lejarre F; Ternant D; Goupille P; Watier H
    Therapie; 2009; 64(1):1-7. PubMed ID: 19463247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humanized antibodies as potential drugs for therapeutic use.
    Merluzzi S; Figini M; Colombatti A; Canevari S; Pucillo C
    Adv Clin Path; 2000 Apr; 4(2):77-85. PubMed ID: 11080787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered antibodies.
    Hudson PJ; Souriau C
    Nat Med; 2003 Jan; 9(1):129-34. PubMed ID: 12514726
    [No Abstract]   [Full Text] [Related]  

  • 20. Engineering therapeutic monoclonal antibodies.
    Liu XY; Pop LM; Vitetta ES
    Immunol Rev; 2008 Apr; 222():9-27. PubMed ID: 18363992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.